These findings underscore that while relative NRG1 mRNA expression in tumor tissue provides the most accurate prediction, both tumor NRG1 protein levels and serum NRG1 levels offer complementary diagnostic value in the prediction of CRPC risk of prostate cancer after ADT. The gene discussed is NRG1; the disease is Familial prostate cancer.